March 16, 2020
Indies Pharma Jamaica Limited reported revenue of $193.72 million, 15% higher than the $168.18 million booked in 2019.
Cost of Sales increased 32% to close at $65.86 million (2019: $49.94 million). Gross profit increased by 8%, amounting to $127.86 million for the period relative to $118.24 million in 2019.
Other operating income for the period rose by 541% to close at $698,370 (2019: $109,005).
Additionally, administrative and other expenses rose by 27%, moving from $72.08 million in 2019 to $91.78 million. According to INDIES, the movement was, “due to costs related to increases in business activity. Significant increases were incurred for rent, lease and set-up costs for the new facility in Freeport, Montego Bay.”
As such, operating profit declined by 21% from $46.27 million recorded in 2019 to $36.78 million for the quarter ended January 31, 2020. There was no finance costs for the quarter ended January 2020 (2019: $77,048), while foreign exchange gain amounted to $2.83 million from a gain of $716,791 in 2019.
Profit before taxation decreased by 16% to close the period at $39.61 million (2019: $46.91 million). INDIES incurred no taxes for the quarter, thus net profit amounted to $39.61 million (2019: $46.91 million). Total Comprehensive Income amounted to $39.61 million for the quarter ended January 31, 2020 relative to $48.61 million in 2019.
Consequently, earnings per share (EPS) for the quarter amounted to $0.03 compared with $0.04 for the corresponding period of last year. The trailing twelve months earnings per share amounted to $0.09. The numbers of shares used in the calculations are 1,332,536,649 units. Notably, INDIES stock price close the trading period on March 16, 2020 at $2.00.
Balance Sheet at a glance:
Assets totalled $927.29 million as at January 31, 2020 relative to $756 million a year prior. The increase in total assets was largely due to a 184% rise in ‘Property, plant and equipment’ to total $244.92 million (2019: $86.32 million).
Total shareholder’s equity amounted to $734.84 million (2019: $717.28 million) with book value per share amounting to $0.55 (2019: $0.54).
Analyst Certification -The views expressed in this research report accurately reflect the personal views of Mayberry Investments Limited Research Department about those issuer (s) or securities as at the date of this report. Each research analyst (s) also certify that no part of their compensation was, is, or will be, directly or indirectly, related to the specific recommendation (s) or view (s) expressed by that research analyst in this research report.
Company Disclosure -The information contained herein has been obtained from sources believed to be reliable, however its accuracy and completeness cannot be guaranteed. You are hereby notified that any disclosure, copying, distribution or taking any action in reliance on the contents of this information is strictly prohibited and may be unlawful. Mayberry may effect transactions or have positions in securities mentioned herein. In addition, employees of Mayberry may have positions and effect transactions in the securities mentioned herein.
